Deutsche Bank AG grew its position in shares of T2 Biosystems Inc (NASDAQ:TTOO) by 101.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 157,785 shares of the medical equipment provider’s stock after buying an additional 79,311 shares during the quarter. Deutsche Bank AG owned 0.36% of T2 Biosystems worth $474,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of T2 Biosystems by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 375,582 shares of the medical equipment provider’s stock worth $1,130,000 after buying an additional 13,552 shares in the last quarter. Bell & Brown Wealth Advisors LLC purchased a new position in shares of T2 Biosystems in the 4th quarter worth $38,000. Pathlight Investors LLC purchased a new position in shares of T2 Biosystems in the 4th quarter worth $117,000. Jane Street Group LLC purchased a new position in shares of T2 Biosystems in the 4th quarter worth $67,000. Finally, Squarepoint Ops LLC grew its stake in shares of T2 Biosystems by 48.7% in the 4th quarter. Squarepoint Ops LLC now owns 53,964 shares of the medical equipment provider’s stock worth $162,000 after buying an additional 17,664 shares in the last quarter. Hedge funds and other institutional investors own 46.23% of the company’s stock.
A number of equities analysts have commented on the stock. HC Wainwright set a $10.00 target price on shares of T2 Biosystems and gave the stock a “buy” rating in a report on Friday, June 7th. Cantor Fitzgerald set a $10.00 target price on shares of T2 Biosystems and gave the stock a “buy” rating in a report on Friday, May 24th. Alliance Global Partners started coverage on shares of T2 Biosystems in a report on Thursday, May 16th. They issued a “buy” rating and a $5.00 target price for the company. ValuEngine lowered shares of T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded shares of T2 Biosystems from a “sell” rating to a “hold” rating in a report on Wednesday, March 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $7.63.
Shares of T2 Biosystems stock traded down $0.13 during trading on Friday, hitting $1.76. The stock had a trading volume of 769,403 shares, compared to its average volume of 772,124. The firm has a market capitalization of $83.80 million, a PE ratio of -1.40 and a beta of 1.86. The company has a current ratio of 0.81, a quick ratio of 0.76 and a debt-to-equity ratio of 0.04. T2 Biosystems Inc has a 12 month low of $1.35 and a 12 month high of $9.98.
T2 Biosystems (NASDAQ:TTOO) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.04). The firm had revenue of $1.80 million during the quarter, compared to the consensus estimate of $1.38 million. T2 Biosystems had a negative return on equity of 325.79% and a negative net margin of 535.26%. T2 Biosystems’s revenue was down 21.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.36) EPS. As a group, sell-side analysts predict that T2 Biosystems Inc will post -1.18 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Deutsche Bank AG Has $474,000 Stake in T2 Biosystems Inc (NASDAQ:TTOO)” was first published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://sundanceherald.com/2019/06/14/deutsche-bank-ag-boosts-stake-in-t2-biosystems-inc-ttoo.html.
T2 Biosystems Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.